Apr 18, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks in Action: PTC Therapeutics Inc (NASDAQ:PTCT), Gilead Sciences Inc (NASDAQ:GILD), Relypsa Inc (NASDAQ:RLYP)

Stocks in Action: PTC Therapeutics Inc (NASDAQ:PTCT), Gilead Sciences Inc (NASDAQ:GILD), Relypsa Inc (NASDAQ:RLYP)

PTC Therapeutics Inc (NASDAQ:PTCT) surged +43.18% and ended at $8.92. The total traded volume was 28.68 million shares and market capitalization arrived at $437.70 million. The stock has a 52-week high price of $74.40 and its 52-week low was recorded at $5.27, while during last trade its minimum price was $6.06 and it gained the highest price of $10.15.

PTC Therapeutics Inc (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7800 that is in Phase II clinical trials for the treatment of spinal muscular atrophy and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

Gilead Sciences Inc (NASDAQ:GILD) reported the increase of +0.10% to close at $98.29 with the overall traded volume of 8.91 million shares. Its market capitalization on last close reached to $133.28 billion. Its beta value stands at 1.03 times. The company has the total of 1.35 billion outstanding shares. Its intraday-low price was $97.62 and its hit its day’s highest price at $98.98.

Gilead Sciences Inc (NASDAQ:GILD) on April 16, 2016 announced results from several Phase 2 and Phase 3 studies evaluating its two investigational, pangenotypic, fixed-dose combination therapies for the treatment of chronic hepatitis C virus (HCV) infection, as well as new data highlighting the potential use of Harvoni® (ledipasvir/sofosbuvir) in adolescents aged 12 to 17. Data were presented this week at The International Liver CongressTM 2016 in Barcelona, Spain.

Results from the open-label, Phase 3 ASTRAL-5 study (PS104), led by David L. Wyles, MD, Associate Professor of Medicine, Division of Infectious Diseases, University of California, San Diego, California, evaluating once-daily SOF/VEL for 12 weeks among patients with HCV genotype 1-6 who are co-infected with HIV demonstrated that SOF/VEL was well-tolerated and resulted in high SVR12 rates. The SVR12 rate was 95 percent (n=99/104) overall, and 100 percent (n=19/19) and 97 percent (n=28/29) in patients with cirrhosis and prior treatment-failure, respectively. Two patients relapsed, while three patients were lost to follow up or withdrew consent. Two patients achieved SVR4 but have not yet returned for the post-treatment week 12 visit. The most common adverse events (>10 percent) were fatigue and headache.

Relypsa Inc (NASDAQ:RLYP) moved down -15.94% to settle at $18.56. Its total traded volume during last trading session was 7.29 million shares. The overall market worth of this company is about $675.71 million. The 52 week range of the stock remained $10.26 – $37.45, while its day’s lowest price was $18.25 and its hit its day’s highest price at $21.49.

Relypsa Inc (NASDAQ:RLYP) announced on April 16, 2016, that on April 1, 2016 the compensation committee of the company’s board of directors granted 3 new employees options to purchase an aggregate of 7,450 shares of the company’s common stock with a per share exercise price of $13.30, the closing trading price on the grant date, and 3,725 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.

 

Comments are closed.